Skip to main content

Table 1 Summary demographics for the individuals with CSF measurements available

From: Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease

 

All

PD cases

Controls

AD cases

Non-neurodegenerativea

N

1960

700

564

386

310

Age (years, 95% CI)

69.3

(62.0–75.0)

66.2

(59.6–73.3)

70.0

(64.9–74.3)

75.0

(70.0–80.0)

64.0

(55.0–73.0)

Males (N, %)

1107

(56.5%)

435

(62.1%)

297

(52.7%)

222

(57.5%)

153

(49.4%)

Alpha-Synuclein

(ZScore(pg/mL))

− 0.02

(− 0.67 to 0.65)

− 0.03

(− 0.70 to 0.60)

0.02

(− 0.71 to 0.71)

0.14

(− 0.57 to 0.80)

− 0.23

(− 0.76 to 0.47)

Amyloid Beta

(ZScore(pg/mL))

− 0.20

(− 0.72 to 0.64)

− 0.20

(− 0.72 to 0.45)

0.11

(− 0.52 to 1.04)

− 0.63

(− 1.00 to − 0.25)

0.03

(− 0.49 to 0.90)

Total Tau

(ZScore(pg/mL))

− 0.27

(− 0.66 to 0.40)

− 0.27

(− 0.70 to 0.39)

− 0.34

(− 0.67 to 0.28)

0.22

(− 0.41 to 1.00)

− 0.50

(− 0.73 to − 0.08)

Phosphorylated Tau

(ZScore(pg/mL))

− 0.25

(− 0.69 to 0.42)

− 0.30

(− 0.72 to 0.35)

− 0.27

(− 0.70 to 0.35)

0.22

(− 0.42 to 0.95)

− 0.48

(− 0.81 to − 0.04)

  1. Concentration values have been standardized using ZScore for comparison purposes. Non-transformed values cannot be compared because there are several measuring methods: SomaScan platform, INNOTEST assay, xMAP-Luminex with INNOBIA AlzBio3, Roche Elecsys cobas e 601 and Euroimmun
  2. aIncludes individuals classified as not being Alzheimer’s disease, Parkinson’s disease or having dementia but neither controls such as essential tremor